New therapeutic opportunities for Alzheimer disease

Abstract

The number of Alzheimer disease (AD) is increasing worldwide and it is still the most common cause of dementia. However, there are limited treatment option with just symptomatic medications. Therefore new disease modifying drugs were in great need for many years for AD treatment. Recently, aducanumab which is beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of AD. Although there are many questions to be answered, this would be the landmark for AD drug that attempt to treat a neurodegenerative disease rather than just symptoms. In this review, I would like to discuss the current development status of dementia treatment, its limitations, and the future opportunity.